Vertex Non-Opioid Pain Candidate Shows Promising Phase II Results

Vertex Pharmaceuticals on Wednesday unveiled positive Phase II data for its investigational, non-opioid voltage-gated sodium channel inhibitor VX-548, significantly easing pain in patients with diabetic peripheral neuropathy.